MicroRNA‑496 suppresses tumor cell proliferation by targeting BDNF in osteosarcoma

Ye,Jing; Xie,Wei; Zuo,Yunzhou; Jing,Guangwu; Tong,Jie

doi:10.3892/etm.2019.8356

MicroRNA‑496 suppresses tumor cell proliferation by targeting BDNF in osteosarcoma

Authors:
- Jing Ye
- Wei Xie
- Yunzhou Zuo
- Guangwu Jing
- Jie Tong
View Affiliations

Affiliations: Department of Orthopedics, Hubei 672 Orthopedics Hospital of Integrated Chinese and Western Medicine, Wuhan, Hubei 430079, P.R. China, Department of Orthopedics, The Sixth Hospital of Wuhan Affiliated to Jianghan University, Wuhan, Hubei 430015, P.R. China
Published online on: December 19, 2019 https://doi.org/10.3892/etm.2019.8356
Pages: 1425-1431

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

MicroRNAs (miRNAs) are integrally involved in biological and pathobiological development. Many studies have demonstrated the abnormal expression of microRNA‑496 (miR‑496) in various human malignant tumors. The present study was designed to investigate the functions and the underlying mechanisms of miR‑496 in osteosarcoma (OS) progression. Reverse transcription‑quantitative polymerase chain reaction (RT‑qPCR) was used to determine the expression of miR‑496 in OS tissues and cell lines. Luciferase activity was used to confirm the interaction between miR‑496 and brain derived neurotrophic factor (BDNF), a downstream gene of miR‑496. RT‑qPCR was also used to quantify BDNF mRNA expression, and the BDNF protein expression level was detected by western blot analysis. In addition, the Cell Counting Kit‑8 (CCK‑8) was used to detect cell viability. The results revealed that the level of miR‑496 expression was significantly reduced in osteosarcoma tissues and cell lines. BDNF was verified to be a direct target gene of miR‑496 and was found to be negatively regulated by miR‑496. Overall, it was demonstrated that miR‑496 inhibits osteosarcoma cell proliferation via inhibition of BDNF. Thus, the miR‑496/BDNF axis may be a novel strategy for the clinical treatment of OS.

View Figures

View References

1	Yang J and Zhang W: New molecular insights into osteosarcoma targeted therapy. Curr Opin Oncol. 25:398–406. 2013. View Article : Google Scholar : PubMed/NCBI
2	Yu W, Zhu J, Wang Y, Wang J, Fang W, Xia K, Shao J, Wu M, Liu B, Liang C, et al: A review and outlook in the treatment of osteosarcoma and other deep tumors with photodynamic therapy: From basic to deep. Oncotarget. 8:39833–39848. 2017.PubMed/NCBI
3	Berner K, Johannesen TB, Berner A, Haugland HK, Bjerkehagen B, Bøhler PJ and Bruland OS: Time-trends on incidence and survival in a nationwide and unselected cohort of patients with skeletal osteosarcoma. Acta Oncol. 54:25–33. 2015. View Article : Google Scholar : PubMed/NCBI
4	Taran SJ, Taran R and Malipatil NB: Pediatric osteosarcoma: An updated review. Indian J Med Paediatr Oncol. 38:33–43. 2017. View Article : Google Scholar : PubMed/NCBI
5	Faisham WI, Mat Saad AZ, Alsaigh LN, Nor Azman MZ, Kamarul Imran M, Biswal BM, Bhavaraju VM, Salzihan MS, Hasnan J, Ezane AM, et al: Prognostic factors and survival rate of osteosarcoma: A single-institution study. Asia Pac J Clin Oncol. 13:e104–e110. 2017. View Article : Google Scholar : PubMed/NCBI
6	Wang S, Zheng S, Hu K, Sun H, Zhang J, Rong G, Gao J, Ding N and Gui B: A predictive model to estimate the pretest probability of metastasis in patients with osteosarcoma. Medicine (Baltimore). 96:e59092017. View Article : Google Scholar : PubMed/NCBI
7	Bartel DP: MicroRNAs: Target recognition and regulatory functions. Cell. 136:215–233. 2009. View Article : Google Scholar : PubMed/NCBI
8	Sonkoly E: The expanding microRNA world in psoriasis. Exp Dermatol. 26:375–376. 2017. View Article : Google Scholar : PubMed/NCBI
9	Mellis D and Caporali A: MicroRNA-based therapeutics in cardiovascular disease: Screening and delivery to the target. Biochem Soc Trans. 46:11–21. 2018. View Article : Google Scholar : PubMed/NCBI
10	Acunzo M and Croce CM: MicroRNA in cancer and cachexia-A mini-review. J Infect Dis. 212 (Suppl 1):S74–S77. 2015. View Article : Google Scholar : PubMed/NCBI
11	Zhai L, Li Y, Lan X and Ai L: MicroRNA-10a-5p suppresses cancer proliferation and division in human cervical cancer by targeting BDNF. Exp Ther Med. 14:6147–6151. 2017.PubMed/NCBI
12	Penna E, Orso F, Cimino D, Tenaglia E, Lembo A, Quaglino E, Poliseno L, Haimovic A, Osella-Abate S, De Pittà C, et al: microRNA-214 contributes to melanoma tumour progression through suppression of TFAP2C. EMBO J. 30:1990–2007. 2011. View Article : Google Scholar : PubMed/NCBI
13	Zhou T, Zhang GJ, Zhou H, Xiao HX and Li Y: Overexpression of microRNA-183 in human colorectal cancer and its clinical significance. Eur J Gastroenterol Hepatol. 26:229–233. 2014. View Article : Google Scholar : PubMed/NCBI
14	Guo P, Lan J, Ge J, Nie Q, Mao Q and Qiu Y: miR-708 acts as a tumor suppressor in human glioblastoma cells. Oncol Rep. 30:870–876. 2013. View Article : Google Scholar : PubMed/NCBI
15	Rubie C, Kölsch K, Halajda B, Eichler H, Wagenpfeil S, Roemer K and Glanemann M: microRNA-496-A new, potentially aging-relevant regulator of mTOR. Cell Cycle. 15:1108–1116. 2016. View Article : Google Scholar : PubMed/NCBI
16	Hu J, Liu T, Zhang Z, Xu Y and Zhu F: Oxidized low-density lipoprotein promotes vascular endothelial cell dysfunction by stimulating miR-496 expression and inhibiting the Hippo pathway effector YAP. Cell Biol Int. 43:528–538. 2019. View Article : Google Scholar : PubMed/NCBI
17	Cates JMM: Simple staging system for osteosarcoma performs equivalently to the AJCC and MSTS systems. J Orthop Res. 36:2802–2808. 2018. View Article : Google Scholar : PubMed/NCBI
18	Di Leva G, Garofalo M and Croce CM: MicroRNAs in cancer. Annu Rev Pathol. 9:287–314. 2014. View Article : Google Scholar : PubMed/NCBI
19	Acunzo M, Romano G, Wernicke D and Croce CM: MicroRNA and cancer-a brief overview. Adv Biol Regul. 57:1–9. 2015. View Article : Google Scholar : PubMed/NCBI
20	Palmini G, Marini F and Brandi ML: What is new in the miRNA world regarding osteosarcoma and chondrosarcoma? Molecules. 22(pii): E4172017. View Article : Google Scholar : PubMed/NCBI
21	Jianwei Z, Fan L, Xiancheng L, Enzhong B, Shuai L and Can L: MicroRNA 181a improves proliferation and invasion, suppresses apoptosis of osteosarcoma cell. Tumour Biol. 34:3331–3337. 2013. View Article : Google Scholar : PubMed/NCBI
22	Chen X, Lv C, Zhu X, Lin W, Wang L, Huang Z, Yang S and Sun J: MicroRNA-504 modulates osteosarcoma cell chemoresistance to cisplatin by targeting p53. Oncol Lett. 17:1664–1674. 2019.PubMed/NCBI
23	Ren J, Yang M, Xu F and Chen J: microRNA-758 inhibits the malignant phenotype of osteosarcoma cells by directly targeting HMGA1 and deactivating the Wnt/β-catenin pathway. Am J Cancer Res. 9:36–52. 2019.PubMed/NCBI
24	Zhu XB, Zhang ZC, Han GS, Han JZ and Qiu DP: Overexpression of miR-214 promotes the progression of human osteosarcoma by regulating the Wnt/β-catenin signaling pathway. Mol Med Rep. 15:1884–1892. 2017. View Article : Google Scholar : PubMed/NCBI
25	Sun X, Dai G, Yu L, Hu Q, Chen J and Guo W: miR-143-3p inhibits the proliferation, migration and invasion in osteosarcoma by targeting FOSL2. Sci Rep. 8:6062018. View Article : Google Scholar : PubMed/NCBI
26	Miao J, Wu S, Peng Z, Tania M and Zhang C: MicroRNAs in osteosarcoma: Diagnostic and therapeutic aspects. Tumour Biol. 34:2093–2098. 2013. View Article : Google Scholar : PubMed/NCBI
27	Mason D, Zhang X, Marques TM, Rose B, Khoury S, Hill M, Deutsch F, Lyons JG, Gama-Carvalho M and Tran N: Human papillomavirus 16 E6 modulates the expression of miR-496 in oropharyngeal cancer. Virology. 521:149–157. 2018. View Article : Google Scholar : PubMed/NCBI
28	Yao X, Yao R, Yi J and Huang F: Upregulation of miR-496 decreases cerebral ischemia/reperfusion injury by negatively regulating BCL2L14. Neurosci Lett. 696:197–205. 2019. View Article : Google Scholar : PubMed/NCBI
29	Rubie C, Zimmer J, Lammert F, Gross JC, Weber SN, Kruse B, Halajda B, Wagner M, Wagenpfeil S and Glanemann M: MicroRNA-496 and mechanistic target of rapamycin expression are associated with type 2 diabetes mellitus and obesity in elderly people. Ann Nutr Metab. 74:279–286. 2019. View Article : Google Scholar : PubMed/NCBI
30	Huang J and Chen L: IL-1β inhibits osteogenesis of human bone marrow-derived mesenchymal stem cells by activating FoxD3/microRNA-496 to repress wnt signaling. Genesis. 55:2017. View Article : Google Scholar
31	Mariga A, Mitre M and Chao MV: Consequences of brain-derived neurotrophic factor withdrawal in CNS neurons and implications in disease. Neurobiol Dis. 97:73–79. 2017. View Article : Google Scholar : PubMed/NCBI
32	Cao L, Liu X, Lin EJ, Wang C, Choi EY, Riban V, Lin B and During MJ: Environmental and genetic activation of a brain-adipocyte BDNF/leptin axis causes cancer remission and inhibition. Cell. 142:52–64. 2010. View Article : Google Scholar : PubMed/NCBI
33	Liu X, McMurphy T, Xiao R, Slater A, Huang W and Cao L: Hypothalamic gene transfer of BDNF inhibits breast cancer progression and metastasis in middle age obese mice. Mol Ther. 22:1275–1284. 2014. View Article : Google Scholar : PubMed/NCBI
34	Qi NN, Tian S, Li X, Wang FL and Liu B: Up-regulation of microRNA-496 suppresses proliferation, invasion, migration and in vivo tumorigenicity of human osteosarcoma cells by targeting eIF4E. Biochimie. 163:1–11. 2019. View Article : Google Scholar : PubMed/NCBI